Released Aug 8, 2023, after the close
10-Q filed Aug 8, 2023, 39 days after period end · 0001628280-23-028287
Q2 2023 · 10-Q
Revenue$27.67M$27.67M +47.3% vs Q2 2022+10.1% vs Q1 2023
Net Income-$17.04M-$17.04M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.22-$0.22 N/M vs Q2 2022N/M vs Q1 2023
Gross Profit$13,602,000+207.3%
Operating Income-$17,449,000N/M
Operating Cash Flowderived-$9,329,000N/M
Free Cash Flowderived-$10,167,000N/M
Margins · derived
Gross margin49.2%+25.6 pt vs Q2 2022
Operating margin-63.1%+142.3 pt vs Q2 2022
Net margin-61.6%+276.8 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $27.67M | $18.78M | $31.02M | $26.06M |
| Net Income | -$17.04M | -$63.54M | -$17.14M | -$13.02M |
| EPS Diluted | -$0.22 | -$0.82 | -$0.23 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR